***Background.*** *Staphylococcus aureus* bacteremia (SAB) requires prolonged intravenous antibiotic courses. Outpatient parenteral antimicrobial therapy (OPAT) is commonly used to complete these courses of therapy. While OPAT is generally considered safe and effective, treatment failures occur. We hypothesized that specific risk factors for treatment failure exist among our patient population.

***Methods.*** To identify factors associated with treatment failure, a retrospective review of all patients receiving OPAT for SAB between January 2011-September 2013 at a large, tertiary-care Veterans Affairs (VA) medical center was conducted. Treatment failure was defined as incomplete therapy, therapy extension, infection relapse, or hospital admission or surgical intervention within 60 days of therapy completion. Chi-square and Student\'s t-test were used to analyze differences between those failing therapy and those who did not; multivariate logistic regression analysis was used to identify risk factors associated with treatment failure.

***Results.*** Of 118 SAB patients treated with OPAT, 101 met inclusion criteria. Treatment failure occurred in 36 (35.6%) patients. In multivariate analysis, heart failure (OR 3.67; CI 1.13 -- 12.0), previous OPAT (OR 14.1; CI 2.02 -- 97.8), immunosuppression (OR 10.5; CI 1.74 -- 63.3), and treatment with daptomycin (OR 9.56; CI 1.89 -- 48.4) were independently associated with treatment failure. No statistically significant differences in failure rates were identified between OPAT settings: rates for home vs skilled nursing facility (SNF) vs the VA community living center (CLC) were 37%, 43%, and 24% respectively (p = 0.33).

***Conclusion.*** In a high complexity veteran patient population, OPAT failure rates for SAB were consistent with those previously reported in the literature. Specific health factors were however associated with higher rates of failure. A nonsignificant trend toward lower failure rates was seen among OPAT patients in the CLC, a VA long-term-care facility possessing its own infectious diseases consultation service. Given the morbidity and cost of SAB treatment failures, similar analyses may benefit other large OPAT programs in order to prospectively optimize the local selection of patients and settings in which successful treatment will most likely occur.
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